Bioactivity:

Mavelertinib is an orally available inhibitor of the EGFR mutant form T790M, a secondarily acquired resistance mutation. Mavelertinib specifically binds to and inhibits EGFR T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFR T79

CAS nr:

1776112-90-3

Purity:

98%

Molecular Weight:

415,43

SMILES:

C=CC(N[C@@H]1CN(C2=NC(NC3=CN(C)N=C3OC)=C4N=CN(C)C4=N2)C[C@H]1F)=O

Formula:

C18H22FN9O2

Pathway:

Target: